RU2744691C2 - Способ уменьшения тяжести или предупреждения ухудшения или прогрессирования симптомов ВРН - Google Patents
Способ уменьшения тяжести или предупреждения ухудшения или прогрессирования симптомов ВРН Download PDFInfo
- Publication number
- RU2744691C2 RU2744691C2 RU2019110137A RU2019110137A RU2744691C2 RU 2744691 C2 RU2744691 C2 RU 2744691C2 RU 2019110137 A RU2019110137 A RU 2019110137A RU 2019110137 A RU2019110137 A RU 2019110137A RU 2744691 C2 RU2744691 C2 RU 2744691C2
- Authority
- RU
- Russia
- Prior art keywords
- leu
- ser
- peptide
- arg
- phe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/258,786 | 2016-09-07 | ||
| US15/258,786 US10532081B2 (en) | 2016-09-07 | 2016-09-07 | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| PCT/IB2017/055187 WO2018047036A1 (en) | 2016-09-07 | 2017-08-29 | Method of ameliorating or preventing the worsening or the progression of symptoms of bph |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019110137A RU2019110137A (ru) | 2020-10-08 |
| RU2019110137A3 RU2019110137A3 (cg-RX-API-DMAC7.html) | 2020-12-07 |
| RU2744691C2 true RU2744691C2 (ru) | 2021-03-15 |
Family
ID=59829424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019110137A RU2744691C2 (ru) | 2016-09-07 | 2017-08-29 | Способ уменьшения тяжести или предупреждения ухудшения или прогрессирования симптомов ВРН |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10532081B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3509620A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2019531278A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102623470B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109890401A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017325033B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019004532A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3036089A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019002698A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2744691C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018047036A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201901449B (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10835538B2 (en) * | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
| EP3934666A1 (en) | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| US11298400B2 (en) | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US20200360466A1 (en) * | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
| US11231421B2 (en) * | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160215031A1 (en) * | 2015-01-27 | 2016-07-28 | Nymox Pharnaceutical Corporation | Method of treating disorders requiring destruction or removal of cells |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3423507A (en) | 1966-02-25 | 1969-01-21 | Schering Corp | Method of treating benign prostratic hypertrophy |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4329364A (en) | 1974-09-11 | 1982-05-11 | Schering Corporation | Antiandrogenic agents and methods for the treatment of androgen dependent disease states |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE2817157A1 (de) | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| FR2465486A1 (fr) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3121153A1 (de) | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie" |
| US4457489A (en) | 1981-07-13 | 1984-07-03 | Gilmore Samuel E | Subsea fluid conduit connections for remote controlled valves |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4659695A (en) | 1985-02-08 | 1987-04-21 | Fernand Labrie | Method of treatment of prostate cancer |
| US4775660A (en) | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
| US4760053A (en) | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| CA1310924C (en) | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
| US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| EP0378924B1 (en) | 1988-12-21 | 1996-11-13 | The General Hospital Corporation | Detection of neurological disease or dysfunction |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| JPH06256387A (ja) | 1991-06-14 | 1994-09-13 | Suetsuna Yoko | 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤 |
| KR100392244B1 (ko) | 1993-04-20 | 2003-11-28 | 더 제너럴 호스피탈 코포레이션 | 신경사단백질유전자발현및알쯔하이머병의검출 |
| ES2178654T3 (es) | 1993-08-12 | 2003-01-01 | Neurotech Sa | Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas. |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| MX9504664A (es) | 1994-03-07 | 1997-05-31 | Dow Chemical Co | Conjugados de dendrimeros bioactivos y/o dirigidos. |
| US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
| JPH11506722A (ja) | 1995-06-07 | 1999-06-15 | ベイラー・カレッジ・オブ・メディスン | 細胞に核酸を送達するための核酸運搬体 |
| BR9711795A (pt) | 1996-03-26 | 2000-06-06 | Razvant T Radulescu | Peptìdeos tendo propriedades antiproliferativas |
| US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
| AU749348B2 (en) | 1997-02-26 | 2002-06-27 | General Hospital Corporation, The | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease |
| AU9655698A (en) | 1997-10-10 | 1999-05-03 | Astra Aktiebolag | Synthetic genes with immunomodulatory effects |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| EP1135494A2 (en) | 1998-12-11 | 2001-09-26 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| AU3517000A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | 50 human secreted proteins |
| JP2002543764A (ja) | 1999-03-19 | 2002-12-24 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 46個のヒト分泌タンパク質 |
| JP2002539842A (ja) | 1999-03-26 | 2002-11-26 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 45個のヒト分泌タンパク質 |
| EP1171462A2 (en) | 1999-03-26 | 2002-01-16 | Human Genome Sciences, Inc. | 49 human secreted proteins |
| EP1220947A2 (en) | 1999-03-26 | 2002-07-10 | Human Genome Sciences, Inc. | 50 human secreted proteins |
| CN1300779A (zh) | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽-人神经元线蛋白17和编码这种多肽的多核苷酸 |
| WO2002000718A2 (en) | 2000-06-26 | 2002-01-03 | Millennium Pharmaceuticals, Inc. | A human calcium channel protein and uses thereof |
| US7259232B1 (en) | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
| CA2325666A1 (fr) | 2000-12-01 | 2002-06-01 | Institut Pasteur | Peptides immunogeniques mutes derives de r9m, polynucleotides les codants et leurs usages therapeutiques |
| US6783969B1 (en) | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
| DE60222745T2 (de) | 2001-03-08 | 2008-07-10 | Nymox Pharmaceutical Corp., St. Laurent | Verwendung von neurofilamentproteinen zur behandlung von tumoren |
| JP2004529179A (ja) | 2001-05-16 | 2004-09-24 | ナイモックス コーポレーション | 神経線維タンパク質のセグメントを使用する細胞死の予防法 |
| BR0209990A (pt) | 2001-05-25 | 2004-06-29 | Nymox Corp | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células |
| DE60217507T2 (de) | 2001-07-19 | 2007-11-15 | Nymox Corp., Saint-Laurent | Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| WO2005113720A2 (en) | 2004-05-19 | 2005-12-01 | Auburn University | A strategy for designing patient-specific anti-cancer drugs |
| PL1994152T3 (pl) * | 2006-02-28 | 2013-05-31 | Nymox Corp | Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek |
| EA200801942A1 (ru) | 2006-03-10 | 2009-02-27 | Наймокс Корпорейшн | Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон |
| US9243035B2 (en) | 2013-11-26 | 2016-01-26 | Nymox Corporation | Peptides effective in the treatment of conditions requiring the removal or destruction of cells |
| US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10172910B2 (en) * | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
-
2016
- 2016-09-07 US US15/258,786 patent/US10532081B2/en not_active Expired - Fee Related
-
2017
- 2017-08-29 AU AU2017325033A patent/AU2017325033B2/en not_active Ceased
- 2017-08-29 KR KR1020197009879A patent/KR102623470B1/ko active Active
- 2017-08-29 RU RU2019110137A patent/RU2744691C2/ru active
- 2017-08-29 EP EP17764662.7A patent/EP3509620A1/en not_active Withdrawn
- 2017-08-29 WO PCT/IB2017/055187 patent/WO2018047036A1/en not_active Ceased
- 2017-08-29 CA CA3036089A patent/CA3036089A1/en active Pending
- 2017-08-29 BR BR112019004532-5A patent/BR112019004532A2/pt not_active Application Discontinuation
- 2017-08-29 JP JP2019512858A patent/JP2019531278A/ja active Pending
- 2017-08-29 EP EP23193577.6A patent/EP4275688A3/en active Pending
- 2017-08-29 MX MX2019002698A patent/MX2019002698A/es unknown
- 2017-08-29 CN CN201780063432.9A patent/CN109890401A/zh active Pending
-
2019
- 2019-03-08 ZA ZA201901449A patent/ZA201901449B/en unknown
-
2022
- 2022-12-09 JP JP2022197208A patent/JP2023036673A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160215031A1 (en) * | 2015-01-27 | 2016-07-28 | Nymox Pharnaceutical Corporation | Method of treating disorders requiring destruction or removal of cells |
Non-Patent Citations (5)
| Title |
|---|
| HIRSCH E. W., Comparative histology of the urethral mucosa and its relation to gonococcal infections, The Journal of Urology, 1927, V. 17, N. 6, p.575-580. * |
| LOGAN Y. T. et al., Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia, The American Journal of Geriatric Pharmacotherapy, 2005, V. 3, N. 2, p.103-114. * |
| СИНЕЛЬНИКОВ Р. Д. и др. Атлас анатомии человека. Том 2: Учение о внутренностях и эндокринных железах, Изд. 7-е, перераб. В 4-х томах. М.: Новая волна, 2009, 248 с.. * |
| СИНЕЛЬНИКОВ Р. Д. и др. Атлас анатомии человека. Том 2: Учение о внутренностях и эндокринных железах, Изд. 7-е, перераб. В 4-х томах. М.: Новая волна, 2009, 248 с.. HIRSCH E. W., Comparative histology of the urethral mucosa and its relation to gonococcal infections, The Journal of Urology, 1927, V. 17, N. 6, p.575-580. ТРЕТЬЯКОВ В. В. и др. Сравнительные результаты лечения больных пожилого и старческого возраста, страдающих доброкачественной гиперплазией предстательной железы и хроническим простатитом в стадии активного воспаления, Вестник Уральской медицинской академической науки, 2013, N. 4, с.64-68. LOGAN Y. T. et al., Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia, The American Journal of Geriatric Pharmacotherapy, 2005, V. 3, N. 2, p.103-114. * |
| ТРЕТЬЯКОВ В. В. и др. Сравнительные результаты лечения больных пожилого и старческого возраста, страдающих доброкачественной гиперплазией предстательной железы и хроническим простатитом в стадии активного воспаления, Вестник Уральской медицинской академической науки, 2013, N. 4, с.64-68. * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190050813A (ko) | 2019-05-13 |
| AU2017325033A1 (en) | 2019-04-11 |
| CA3036089A1 (en) | 2018-03-15 |
| KR102623470B1 (ko) | 2024-01-09 |
| RU2019110137A3 (cg-RX-API-DMAC7.html) | 2020-12-07 |
| EP3509620A1 (en) | 2019-07-17 |
| US20180064785A1 (en) | 2018-03-08 |
| AU2017325033B2 (en) | 2024-11-14 |
| EP4275688A3 (en) | 2024-01-17 |
| US10532081B2 (en) | 2020-01-14 |
| EP4275688A2 (en) | 2023-11-15 |
| RU2019110137A (ru) | 2020-10-08 |
| NZ751862A (en) | 2025-11-28 |
| JP2019531278A (ja) | 2019-10-31 |
| ZA201901449B (en) | 2020-11-25 |
| WO2018047036A1 (en) | 2018-03-15 |
| JP2023036673A (ja) | 2023-03-14 |
| CN109890401A (zh) | 2019-06-14 |
| MX2019002698A (es) | 2020-07-22 |
| BR112019004532A2 (pt) | 2019-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3307299B1 (en) | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations | |
| EP3324994B1 (en) | Nx-1207 for use in methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia | |
| AU2017283820B2 (en) | Neural thread peptide for preventing or reducing the progression of prostate cancer | |
| AU2017325033B2 (en) | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH | |
| RU2739916C1 (ru) | Композиции и способы для улучшения сексуальной функции | |
| RU2721538C1 (ru) | Способ предупреждения возникновения или снижения частоты возникновения острой задержки мочи | |
| CA2992174C (en) | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations | |
| HK1260762B (en) | Neural thread peptide for preventing or reducing the progression of prostate cancer | |
| HK1260762A1 (en) | Neural thread peptide for preventing or reducing the progression of prostate cancer | |
| HK1254080B (en) | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations | |
| HK1249007B (en) | Nx-1207 for use in methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |